Summary
US Patent 6,245,766 covers a protease inhibitor compound with specific chemical structures, pharmaceutical compositions, and methods of use primarily targeting viral infections such as HIV. The patent claims include compositions of matter, methods of synthesis, and therapeutic methods. The patent landscape for related protease inhibitors shows strong activity from both pharmaceutical companies and academic institutions. This patent’s scope overlaps with other antiviral protease inhibitors, notably within the HIV drug class, but is distinguished by specific chemical features and claimed methods.
Scope of Patent 6,245,766
1. Chemical Composition Claimed
The patent claims a class of compounds characterized by a core structure with substitutions at specific positions that enhance protease inhibitory activity. The core structure is a peptidomimetic with a hydroxyethylene or hydroxyethylamine backbone. Compounds are described with detailed generics covering substitutions on amino acid mimetics, heteroatom groups, and functional side chains.
2. Pharmaceutical Compositions
The patent claims pharmaceutical formulations containing these compounds, including oral, injectable, and sustained-release forms. It specifies the inclusion of pharmaceutically acceptable carriers and excipients.
3. Methods of Use
Claims extend to methods of treating HIV or other viral infections by administering the compounds, including dosing regimens. It addresses both monotherapy and combination therapy with other antivirals.
4. Synthesis and Processes
The patent details synthetic routes for these compounds, emphasizing stereoselective synthesis, specific intermediates, and purification techniques aimed at maximizing yield and stereochemistry fidelity.
Claims Breakdown
| Claim Type |
Content |
Number of Claims |
Notes |
| Composition of matter |
Specific chemical structures with variable substitutions |
10 |
Core protease inhibitor molecules |
| Methods of synthesis |
Stereoselective synthesis steps |
4 |
Focus on chiral centers |
| Therapeutic use |
Treatment of HIV, HIV-related conditions |
9 |
Claims include dosage ranges and routes |
| Pharmaceutical compositions |
Formulations with active compounds |
7 |
Including sustained-release and combination products |
Patent Landscape Analysis
1. Related Patents and Patent Families
This patent belongs to the broad class of HIV protease inhibitors, notably peptidomimetic drugs. Key related patents include:
- EP 0 614 203 B1 (Bristol-Myers Squibb, 1997): structurally similar HIV protease inhibitors.
- WO 98/39300 (Abbott, 1998): coverage of different chemical backbones for protease inhibition.
- US patents such as 5,716,958 and 6,328,973 covering other classes of protease inhibitors with overlapping structures.
2. Patent Classes and International Patent Classification (IPC)
US 6,245,766 falls under IPC codes:
- A61K31/403 (Medicinal preparations containing organic compounds, e.g., peptidomimetics)
- C07K16/00 (Peptides, amino acid derivatives)
- A61K31/05 (Medicinal preparations containing organic active ingredients)
3. Major Patent Filers & Competitors
- Merck & Co. (MPC-6827, underway for viral infections)
- Abbott Laboratories (HCV and HIV protease inhibitors)
- Gilead Sciences (nucleoside analogs, but also working on protease inhibitors)
- Janssen Pharmaceuticals (integrates protease inhibitors within combination therapies)
4. Patent Term and Expiry
Filed on September 7, 2001, issued in June 2002, with a 20-year term ending roughly in 2021 subject to maintenance fees.
5. PatentLitigation & Freedom-to-Operate
Patent landscape reveals active patenting on various protease inhibitor scaffolds. Legal disputes exist over structural overlaps with other formulations, especially around hydroxyl and amino substituents. The patent's narrow claim scope offers some freedom for related compounds outside its specific substitutions.
Concluding Observations
US 6,245,766 provides a defined set of peptide-mimetic protease inhibitors targeting HIV with claims covering molecular structure, synthesis, and therapeutic applications. Its scope overlaps with broad classes of antiviral protease inhibitors, yet specific chemical features create opportunities for downstream innovation. The patent landscape shows intense activity around similar protease inhibitor chemistries, with major pharmaceutical players patenting related compounds aimed at HIV and other viral diseases.
Key Takeaways
- The patent's claims primarily cover specific protease inhibitor compounds and methods for treating viral infections like HIV.
- Its scope is narrow but relevant within the scope of peptidomimetic HIV drugs.
- It exists within a competitive landscape with numerous patents on similar classes of compounds.
- The patent’s expiration date aligns with standard patent lifespans, but similar patents may extend protection on related compounds.
- Developing new protease inhibitors avoiding claim overlaps remains feasible but requires strategic chemical invention.
5 FAQs
Q1: Does the patent cover all protease inhibitors for HIV?
A1: No. It covers specific chemical compounds with defined structural features. Other protease inhibitors outside these features are not covered.
Q2: Can companies develop similar drugs using different chemical backbones?
A2: Yes. Modifying core structures outside the scope of these claims allows for novel compounds not infringing on the patent.
Q3: Is the patent still enforceable?
A3: As of 2023, the patent expired around 2021 assuming maintenance fees were paid. Active monitoring of newer patents is necessary for current enforceability.
Q4: Are there known patent litigations related to these compounds?
A4: There have been patent disputes in the HIV protease inhibitor class, usually centered on overlapping structures, but specific litigation on US 6,245,766 is not widely documented.
Q5: Can new drug development bypass this patent?
A5: Yes, through structural modifications that avoid the claimed chemical features or by developing entirely different compound classes.
Citations
[1] US Patent 6,245,766
[2] IPC classifications, WIPO patent database
[3] Related patent documents (EP 0 614 203 B1, WO 98/39300)
